More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer
Posted innews Oncology Urology

More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer

Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while significantly increasing the risk of long-term gastrointestinal toxicity.
Integrated Multidisciplinary Care Slashes Radiotherapy Interruptions in Head and Neck Cancer: Results from the SHINE-MDT Randomized Trial
Posted innews Oncology Otorhinolaryngology

Integrated Multidisciplinary Care Slashes Radiotherapy Interruptions in Head and Neck Cancer: Results from the SHINE-MDT Randomized Trial

A randomized clinical trial demonstrates that the SHINE-MDT framework significantly reduces radiotherapy interruptions and improves nutritional, psychological, and quality-of-life outcomes for patients with head and neck cancer, offering a new standard for holistic supportive care during intensive oncology treatments.
Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority
Posted innews Oncology Otorhinolaryngology

Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority

A multicenter propensity-matched cohort comparing adjuvant proton beam radiotherapy (PBRT) with intensity-modulated radiotherapy (IMRT) for olfactory neuroblastoma found no definitive differences in local control, recurrence-free survival, overall survival, or clinically meaningful reductions in grade ≥2 radiation toxicities, but estimates were imprecise.
Radiotherapy for Growing Vestibular Schwannomas: Real‑World Tumor Control and What It Means for Practice
Posted innews Oncology Otorhinolaryngology

Radiotherapy for Growing Vestibular Schwannomas: Real‑World Tumor Control and What It Means for Practice

An international multicenter cohort of 1,883 patients with radiologically growing vestibular schwannomas treated first‑line with radiotherapy showed a 10‑year tumor control rate of 76.1% (primary definition). Control estimates varied widely by growth definition, underscoring the clinical importance of outcome metrics.
Personalizing Radiotherapy in Ductal Carcinoma In Situ Using a 12-Gene Expression Assay: Insights from a Prospective Clinical Trial
Posted inOB/GYN & Women's Health Oncology Radiology Specialties

Personalizing Radiotherapy in Ductal Carcinoma In Situ Using a 12-Gene Expression Assay: Insights from a Prospective Clinical Trial

This clinical trial prospectively evaluates how a 12-gene expression assay (DCIS score) guides postoperative radiotherapy decisions after breast-conserving surgery in ductal carcinoma in situ, showing tailored radiotherapy use may reduce ipsilateral breast events.
Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial
Posted innews Oncology Urology

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial

A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiotherapy alone, with limited toxicity.